Spots Global Cancer Trial Database for antibody drug conjugate (adc)
Every month we try and update this database with for antibody drug conjugate (adc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors | NCT04941339 | Advanced Solid ... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) | NCT04742153 | Advanced or Met... | MRG002 | 18 Years - | Shanghai Miracogen Inc. | |
| A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors | NCT04843709 | Advanced or Met... | MRG004A | 18 Years - | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer | NCT04839510 | Locally Advance... Metastatic Urot... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer | NCT04838548 | Carcinoma, Non-... | MRG003 | 18 Years - | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). | NCT05141786 | Non-small- Cell... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer | NCT04837508 | Advanced or Met... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein | NCT03368196 | Adenocarcinoma,... Neoplasm, Breas... | DS-8201a | 20 Years - | Daiichi Sankyo | |
| A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. | NCT05188209 | Advanced or Met... Advanced or Met... | MRG003 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors | NCT04941339 | Advanced Solid ... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG003 in Patients With Advanced Solid Tumors | NCT04868344 | Advanced Solid ... | MRG003 | 18 Years - | Shanghai Miracogen Inc. | |
| Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors | NCT04084366 | Locally Advance... | OBI-999 OBI-999 | 18 Years - | OBI Pharma, Inc | |
| A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). | NCT05141786 | Non-small- Cell... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients | NCT05263869 | Breast Cancer W... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer | NCT05754853 | Advanced or Met... | MRG002 Docetaxel Injec... Paclitaxel Inje... Gemcitabine Hyd... Pemetrexed Diso... | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein | NCT03368196 | Adenocarcinoma,... Neoplasm, Breas... | DS-8201a | 20 Years - | Daiichi Sankyo | |
| A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors | NCT05688605 | Advanced Solid ... | MRG003+HX008 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer | NCT04924699 | Advanced Breast... Metastatic Brea... | MRG002 Trastuzumab Emt... | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer | NCT04837508 | Advanced or Met... | MRG002 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | NCT05338957 | Advanced Malign... | MRG002+HX008 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | NCT04868162 | Recurrent or Me... | MRG003 | 18 Years - | Shanghai Miracogen Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | NCT05338957 | Advanced Malign... | MRG002+HX008 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | NCT02564900 | Advanced Solid ... | DS-8201a (DP1) DS-8201a (DP2) DS-8201a (DP) | 18 Years - | Daiichi Sankyo | |
| A Study of MRG003 in Patients With Advanced Solid Tumors | NCT04868344 | Advanced Solid ... | MRG003 | 18 Years - | Shanghai Miracogen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
